Financial Review: IGM Biosciences (NASDAQ:IGMS) and Advanz Pharma (NASDAQ:CXRXF)

Share on StockTwits

IGM Biosciences (NASDAQ:IGMS) and Advanz Pharma (OTCMKTS:CXRXF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Institutional & Insider Ownership

34.8% of IGM Biosciences shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IGM Biosciences and Advanz Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IGM Biosciences 0 0 4 0 3.00
Advanz Pharma 0 1 0 0 2.00

IGM Biosciences currently has a consensus price target of $28.25, suggesting a potential downside of 2.85%. Given IGM Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe IGM Biosciences is more favorable than Advanz Pharma.

Earnings and Valuation

This table compares IGM Biosciences and Advanz Pharma’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IGM Biosciences N/A N/A N/A N/A N/A
Advanz Pharma $536.99 million 0.43 $1.47 billion N/A N/A

Advanz Pharma has higher revenue and earnings than IGM Biosciences.

Profitability

This table compares IGM Biosciences and Advanz Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IGM Biosciences N/A N/A N/A
Advanz Pharma -50.87% -93.24% -7.06%

Summary

IGM Biosciences beats Advanz Pharma on 7 of the 8 factors compared between the two stocks.

About IGM Biosciences

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.

Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

iPath US Treasury Steepener ETN  Stock Price Down 0.7%
iPath US Treasury Steepener ETN Stock Price Down 0.7%
Octopus Aim VCT 2  Shares Up 0.7%
Octopus Aim VCT 2 Shares Up 0.7%
Siemens  Trading Up 2%
Siemens Trading Up 2%
Scandium International Mining  Trading Down 22.4%
Scandium International Mining Trading Down 22.4%
Neumann Capital Management LLC Sells 2,000 Shares of Chevron Co.
Neumann Capital Management LLC Sells 2,000 Shares of Chevron Co.
Horizns Marijuna Lf Cl A Unt Etf  Shares Up 0.2%
Horizns Marijuna Lf Cl A Unt Etf Shares Up 0.2%


© 2006-2020 Ticker Report